Carlyle Group Inc. Phathom Pharmaceuticals, Inc. Transaction History
Carlyle Group Inc.
- $80.8 Million
- Q1 2025
A detailed history of Carlyle Group Inc. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Carlyle Group Inc. holds 3,496,808 shares of PHAT stock, worth $32.9 Million. This represents 27.15% of its overall portfolio holdings.
Number of Shares
3,496,808
Previous 3,496,808
-0.0%
Holding current value
$32.9 Million
Previous $28.4 Million
22.79%
% of portfolio
27.15%
Previous 28.4%
Shares
2 transactions
Others Institutions Holding PHAT
# of Institutions
142Shares Held
59.2MCall Options Held
94KPut Options Held
55.5K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$95 Million3.99% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$70.2 Million20.28% of portfolio
-
Invesco Ltd. Atlanta, GA3.65MShares$34.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$27.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.78MShares$26.1 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $368M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...